ProMIS Neurosciences Inc

Insider Kirwin Patrick’s $11.33 buy of 4,000 ProMIS Neurosciences shares amid an 8 % weekly decline signals confidence that Phase II data will spark a valuation rebound, making it a strategic buy‑and‑hold for biotech investors.

Insider buying surge at ProMIS Neurosciences shows strong confidence in its precision‑medicine pipeline—potential upside if clinical milestones hit.

ProMIS Neurosciences insider buying surge signals confidence in PMN310 breakthrough—watch the 60‑day post‑milestone window for a potential price rebound.

Insider buying surges at ProMIS Neurosciences as ABG V‑SIV IX and AB G Management purchase 700k shares, betting on PMN310 milestone data to lift shares.

Insider buying spurs confidence in ProMIS Neurosciences: key executives purchase 15k+ shares and warrants, signaling optimism about its precision‑medicine pipeline amid volatile market conditions.

ABG Management’s fresh stake in ProMIS signals confidence in its PMN310 pipeline—an insider bet that could spark a price surge when milestone data drops.